Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 115 Published: April 05, 2022 Report Code: GDGMDHC22188IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    iSpeech

The Mild Cognitive Impairment pipeline market report provides a comprehensive overview of the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects.

Mild Cognitive Impairment Pipeline Drugs Market by Key Targets

In the Mild Cognitive Impairment pipeline drugs market, the key targets are Amyloid Beta A4 Protein, Beta 2 Adrenergic Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Glucagon Like Peptide 1 Receptor, Microtubule Associated Protein Tau, Acetylcholinesterase, Bcr-Abl Tyrosine Kinase, and Brain Derived Neurotrophic Factor.

Key Targets in the Mild Cognitive Impairment Pipeline Drugs Market

Key Targets in the Mild Cognitive Impairment Pipeline Drugs Market

For more target insights, download a free report sample

Key MoA in the Mild Cognitive Impairment Pipeline Drugs Market

Some of the key mechanisms of action in the Mild Cognitive Impairment pipeline drugs market are Amyloid Beta A4 Protein Inhibitor, Beta 2 Adrenergic Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Agonist, Beta 2 Adrenergic Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Glucagon Like Peptide 1 Receptor Agonist, Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, and Bcr-Abl Tyrosine Kinase Inhibitor.

Mild Cognitive Impairment Pipeline Drugs Market Analysis, by MoA

Mild Cognitive Impairment Pipeline Drugs Market Analysis, by MoA

To get more insights on key MoA, download a free sample report

Mild Cognitive Impairment Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Mild Cognitive Impairment pipeline drug market are oral, intravenous, subcutaneous, inhalational, nasal, buccal, intraarticular, and sublingual. Oral has the maximum number of pipeline products.

Mild Cognitive Impairment Pipeline Drugs Market Analysis, by RoA

Mild Cognitive Impairment Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Mild Cognitive Impairment Pipeline Drugs Market

The key molecule types in the Mild Cognitive Impairment pipeline drugs market are Small Molecule, Monoclonal Antibody, Synthetic Peptide, Peptide, Antibody, Cell Therapy, Gene Therapy, Recombinant Protein, And Subunit Vaccine. Small molecule has the maximum number of pipeline products.

Mild Cognitive Impairment Pipeline Drugs Market, by Molecule Types

Mild Cognitive Impairment Pipeline Drugs Market, by Molecule Types

To get more insights on key molecule types, download a free sample report

Major Companies in the Mild Cognitive Impairment Pipeline Drugs Market

Some of the major companies in the Mild Cognitive Impairment pipeline drugs market are CuraSen Therapeutics Inc, AgeneBio Inc, Merck & Co Inc, Actinogen Medical Ltd, Acumen Pharmaceuticals Inc, Addex Therapeutics Ltd, Aptinyx Inc, Araclon Biotech SL, AstraZeneca Plc, and Biomed Industries Inc.

Mild Cognitive Impairment Pipeline Drugs Market, by Major Companies

Mild Cognitive Impairment Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Mild Cognitive Impairment Pipeline Drugs Market Overview

Key Targets Amyloid Beta A4 Protein, Beta 2 Adrenergic Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Glucagon Like Peptide 1 Receptor, Microtubule Associated Protein Tau, Acetylcholinesterase, Bcr-Abl Tyrosine Kinase, and Brain Derived Neurotrophic Factor
Key Mechanisms of Action Amyloid Beta A4 Protein Inhibitor, Beta 2 Adrenergic Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Agonist, Beta 2 Adrenergic Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Glucagon Like Peptide 1 Receptor Agonist, Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, and Bcr-Abl Tyrosine Kinase Inhibitor
Key Routes of Administration Oral, Intravenous, Subcutaneous, Inhalational, Nasal, Buccal, Intraarticular, and Sublingual
Key Molecule Types Small Molecule, Monoclonal Antibody, Synthetic Peptide, Peptide, Antibody, Cell Therapy, Gene Therapy, Recombinant Protein, and Subunit Vaccine
Major Companies CuraSen Therapeutics Inc, AgeneBio Inc, Merck & Co Inc, Actinogen Medical Ltd, Acumen Pharmaceuticals Inc, Addex Therapeutics Ltd, Aptinyx Inc, Araclon Biotech SL, AstraZeneca Plc, and Biomed Industries Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment
  • The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mild Cognitive Impairment therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mild Cognitive Impairment therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Mild Cognitive Impairment

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

Actinogen Medical Ltd

Acumen Pharmaceuticals Inc

Addex Therapeutics Ltd

AgeneBio Inc

Aptinyx Inc

Araclon Biotech SL

AstraZeneca Plc

Biomed Industries Inc

CereSpir Inc

CuraSen Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

FUJIFILM Toyama Chemical Co Ltd

Gray Matter

Grespo AB

ImmunoChem Therapeutics LLC

IntelGenx Corp

INVENT Pharmaceuticals Inc

Jupiter Neurosciences Inc

KeifeRx LLC

Merck & Co Inc

NeurAegis Inc

Neuraly Inc

NKGen Biotech Inc

NLS Pharmaceutics AG

Novartis AG

Novo Nordisk AS

Octapharma AG

Partner Therapeutics Inc

Pfizer Inc

ProNeurogen Inc

Sage Therapeutics Inc

SBI Pharmaceuticals Co Ltd

SciSparc Ltd

Shackelford Pharma Inc

TauRx Therapeutics Ltd

UCB SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Mild Cognitive Impairment – Overview

Mild Cognitive Impairment – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Mild Cognitive Impairment – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mild Cognitive Impairment – Companies Involved in Therapeutics Development

Mild Cognitive Impairment – Drug Profiles

Mild Cognitive Impairment – Dormant Projects

Mild Cognitive Impairment – Discontinued Products

Mild Cognitive Impairment – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Mild Cognitive Impairment, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Mild Cognitive Impairment – Dormant Projects, 2022

Mild Cognitive Impairment – Dormant Projects, 2022 (Contd..1)

Mild Cognitive Impairment – Dormant Projects, 2022 (Contd..2)

Mild Cognitive Impairment – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Mild Cognitive Impairment, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

In the Mild Cognitive Impairment pipeline drugs market the key targets are Amyloid Beta A4 Protein, Beta 2 Adrenergic Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Glucagon Like Peptide 1 Receptor, Microtubule Associated Protein Tau, Acetylcholinesterase, Bcr-Abl Tyrosine Kinase, and Brain Derived Neurotrophic Factor.

In the Mild Cognitive Impairment pipeline drugs market the key mechanisms of action are Amyloid Beta A4 Protein Inhibitor, Beta 2 Adrenergic Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Agonist, Beta 2 Adrenergic Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Glucagon Like Peptide 1 Receptor Agonist, Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, and Bcr-Abl Tyrosine Kinase Inhibitor.

The key routes of administration in the Mild Cognitive Impairment pipeline drug market are Oral, Intravenous, Subcutaneous, Inhalational, Nasal, Buccal, Intraarticular, and Sublingual. Subcutaneous has the maximum number of pipeline products.

The key molecule types in the Mild Cognitive Impairment pipeline drug market are Small Molecule, Monoclonal Antibody, Synthetic Peptide, Peptide, Antibody, Cell Therapy, Gene Therapy, Recombinant Protein, and Subunit Vaccine.

In the Mild Cognitive Impairment pipeline drugs market the major companies are CuraSen Therapeutics Inc, AgeneBio Inc, Merck & Co Inc, Actinogen Medical Ltd, Acumen Pharmaceuticals Inc, Addex Therapeutics Ltd, Aptinyx Inc, Araclon Biotech SL, AstraZeneca Plc, and Biomed Industries Inc.

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.